Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers
This article was originally published in PharmAsia News
Eisai took the biggest hit in the latest price revisions due to its lead products exceeding peak sales in Japan, according to analysts.
You may also be interested in...
Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
SINGAPORE - Chugai attributes the success of its development program for the novel interleukin-6 receptor-inhibiting Actemra (tocilizumab) to its partnership with Roche, Chugai Business Development General Manager Kimio Nishimura told Biomedical Asia 2008 attendees in Singapore April 16
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?